



Treatment of central precocious puberty using low dose GnRH analogs (GnRHa)

Rahul Jahagirdar^{*}, Vaman Khadilkar, Ruma Deshpande

From 8th APPES Biennial Scientific Meeting Darwin, Australia. 29 October – 1 November 2014

Aims

1. To study the efficacy of lower dose GnRHa in pubertal suppression and bone age advancement.

2. To study if low dose of GnRHa avoided the need for concomitant use of GH therapy while causing adequate pubertal suppression.

Methods

Clinical Records of 17 children (16 girls and 1 boy) were retrospectively analyzed over a period of 24 months (Mar 2012 to Mar 2014).

All children satisfied the criteria for precocity based on clinical features, radiological assessment and GnRHa stimulation test. All 16 girls had idiopathic precocious puberty and the only boy had hypothalamic hamartoma.

The mean age of presentation was 6. 9 years.

All children received GnRHa as monthly injection in an average dose of 190 μ gm /kg/month and were regularly followed for evaluation of pubertal suppression, height gain and Bone age advancement.


Results

Over a 24 month study period, children showed good pubertal suppression with a comparatively low dose of GnRHa (190 μ gm/kg/month). Mean LH post stimulation while on therapy was 2.31 miu/ml suggesting adequate suppression, average annual growth velocity was 5.1 cm. Advancement in bone age was 1.4 years over a period of 2 years.

Conclusion

1. Children with CPP could be managed with a lower dose of GnRHa to achieve adequate pubertal suppression (190 μ gm/kg/month as opposed to the standard recommended dose of 300 - 750 μ gm/kg/month).

Bharati Vidyapeeth University Medical College, Pune, Maharashtra, India



Published: 28 April 2015

doi:10.1186/1687-9856-2015-S1-P89 Cite this article as: Jahagirdar *et al.*: Treatment of central precocious puberty using low dose GnRH analogs (GnRHa). International Journal of Pediatric Endocrinology 2015 2015(Suppl 1):P89.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

BioMed Central

Submit your manuscript at www.biomedcentral.com/submit



© 2015 Jahagirdar et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.